243 related articles for article (PubMed ID: 34387082)
1. Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.
Tan S; Gong X; Liu H; Yao X
ACS Chem Neurosci; 2021 Sep; 12(17):3214-3224. PubMed ID: 34387082
[TBL] [Abstract][Full Text] [Related]
2. Molecular Modeling Study on the Interaction Mechanism between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling.
Tan S; Zhang Q; Wang J; Gao P; Xie G; Liu H; Yao X
ACS Chem Neurosci; 2022 Mar; 13(5):599-612. PubMed ID: 35188741
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2.
Park H; Kim T; Kim K; Jang A; Hong S
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361616
[TBL] [Abstract][Full Text] [Related]
4. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
5. Identification of LRRK2 Inhibitors through Computational Drug Repurposing.
Tan S; Lu R; Yao D; Wang J; Gao P; Xie G; Liu H; Yao X
ACS Chem Neurosci; 2023 Feb; 14(3):481-493. PubMed ID: 36649061
[TBL] [Abstract][Full Text] [Related]
6. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
[TBL] [Abstract][Full Text] [Related]
7. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach.
Agrahari AK; Doss GPC; Siva R; Magesh R; Zayed H
J Theor Biol; 2019 May; 469():163-171. PubMed ID: 30844370
[TBL] [Abstract][Full Text] [Related]
9. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.
Baidya AT; Deshwal S; Das B; Mathew AT; Devi B; Sandhir R; Kumar R
Bioorg Chem; 2024 Feb; 143():106972. PubMed ID: 37995640
[TBL] [Abstract][Full Text] [Related]
10. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
Göring S; Taymans JM; Baekelandt V; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
[TBL] [Abstract][Full Text] [Related]
12. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
Nagarajan N; Chellam J; Kannan RR
J Cell Biochem; 2018 Jun; 119(6):4878-4889. PubMed ID: 29369408
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
15. Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods.
Gancia E; De Groot M; Burton B; Clark DE
Bioorg Med Chem Lett; 2017 Jun; 27(11):2520-2527. PubMed ID: 28408230
[TBL] [Abstract][Full Text] [Related]
16. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
17. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
[TBL] [Abstract][Full Text] [Related]
18. Development and biological evaluation of[
Malik N; Kornelsen R; McCormick S; Colpo N; Merkens H; Bendre S; Benard F; Sossi V; Schirrmacher R; Schaffer P
Eur J Med Chem; 2021 Feb; 211():113005. PubMed ID: 33248850
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the WD40 domain dimer of LRRK2.
Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
[TBL] [Abstract][Full Text] [Related]
20. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ
Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
